AR (Androgen Receptor)

7 drugs

Predictive biomarker for patient selection in 7 indications

Approved Drugs

Indications

Companies

AR (Androgen Receptor) is a precision-medicine biomarker linked to 7 FDA-approved targeted drugs from 7 companies, spanning 7 indications including Metastatic Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer. Explore the targeted therapies, indications, testing methods, and companies developing AR (Androgen Receptor) drugs below.

Search AR (Androgen Receptor) Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting AR (Androgen Receptor)

Drug	Company	Therapeutic Area
APALUTAMIDE	ZYDUS LIFESCIENCES	Oncology
CASODEX	ANI PHARMS	Oncology
ERLEADA	Johnson & Johnson	Oncology
NILANDRON	ADVANZ PHARMA	Oncology
NUBEQA	Bayer	Oncology
WINLEVI	Sun Pharma	Dermatology
XTANDI	ASTELLAS	Oncology

AR (Androgen Receptor) Indications

Metastatic Prostate Cancer Metastatic Castration-Sensitive Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer Acne Vulgaris Prostate Cancer Castration-Resistant Prostate Cancer Non-Metastatic Castration-Sensitive Prostate Cancer

Companies with AR (Androgen Receptor) Drugs

ANI PHARMS Johnson & Johnson Sun Pharma Bayer ASTELLAS ADVANZ PHARMA ZYDUS LIFESCIENCES